SAGICO(SGMT)

Focus: SAGICO is a public medical device company focused on spinal analytics and implants in the musculoskeletal space, operating from San Mateo, CA with minimal commercial revenue.

Musculoskeletal

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About SAGICO

AI assessmentNot Hiring

No open roles listed right now. Follow SAGICO to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$2M

FY2024

Key Products

Spinal Analytics & Implants Platform

Musculoskeletal disorders

Early Development

Core portfolio remains largely undisclosed with minimal commercial traction ($2M FY 2024 revenue).

Pipeline & Clinical Trials

No episiotomy

Anal Sphincter Injury

N/A

Help build intelligence for SAGICO

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides liquidity and equity transparency for compensation — ticker SGMT offers stock-based upside
R&D spending of $38M (FY 2025) demonstrates commitment to product development in high-margin medical devices
Focused niche in spinal implants and analytics offers deep technical specialization opportunity in growing orthopedic segment

Watch Out For

Severe cash burn: -$45.6M net loss (FY 2025) on only $2M revenue (FY 2024) signals runway pressure and potential restructuring risk
Zero active job openings and no hiring data suggests company may be in contraction or reallocation phase, not expansion
Minimal pipeline clarity: single program in unclear phase status with no active trials raises questions about product viability and near-term catalysts

Generated by Claude from SAGICO's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Clinical Trials (1)

NCT02356237The Effect of Episiotomy on Maternal and Fetal Outcomes (EPITRIAL)

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

R&D Spend

$38M94%

Net Income

-$46M

Cash

$76M

Source: SEC 10-K Filing